No­vo and Viking present new MASH da­ta, but an­a­lysts re­main con­fi­dent in Madri­gal's Rezd­if­fra

No­vo Nordisk and Viking Ther­a­peu­tics took to the an­nu­al Liv­er Meet­ing to make the case for their ex­per­i­men­tal MASH drugs as they chase Madri­gal Phar­ma­ceu­ti­cals’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER